Recurrent Primary Peritoneal Carcinoma Completed Phase 2 Trials for Sorafenib (DB00398)

IndicationStatusPhase
DBCOND0031168 (Recurrent Primary Peritoneal Carcinoma)Completed2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00096200Sorafenib With or Without Paclitaxel and Carboplatin in Treating Patients With Recurrent Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube CancerTreatment